News

Gufic Biosciences Limited informed the BSE Limited and National Stock Exchange of India Limited that it received a certificate from MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, confirming the handling of securities received for dematerialization during the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Gufic Biosciences Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Gufic BioSciences announced that the 42th Annual General Meeting(AGM) of the company will be held on 4 September 2026.

Net profit of Gufic BioSciences rose 183.68% to Rs 21.90 crore in the quarter ended March 2026 as against Rs 7.72 crore during the previous quarter ended March 2025. Sales rose 22.83% to Rs 251.82 crore in the quarter ended March 2026 as against Rs 205.02 crore during the previous quarter ended March 2025.For the full year,net profit declined 7.81% to Rs 64.21 crore in the year ended March 2026 as against Rs 69.65 crore during the previous year ended March 2025. Sales rose 15.15% to Rs 944.01 crore in the year ended March 2026 as against Rs 819.81 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales251.82205.02 23 944.01819.81 15 OPM %18.7512.87 -16.0316.60 - PBDT36.6018.37 99 117.38115.21 2 PBT28.9510.52 175 86.5594.14 -8 NP21.907.72 184 64.2169.65 -8 Powered by Capital Market - Live News

Gufic BioSciences announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.